Renounceable Rights Issue Prospectus
March 25, 2020
Imagion Biosystems Limited has released the Renounceable Rights Issue Prospectus: For a renounceable pro rata offer of 204,512,879 Shares at an issue price of $0.01
Category: Investor updates
Appendix 3B — Renounceable Rights Issue
March 25, 2020
Imagion Biosystems Limited has released Appendix 3B — Renounceable Rights Issue. Read Appendix 3B.
Pro-Rata Renounceable Rights Issue
March 25, 2020
Imagion Biosystems Limited has released “Pro-Rata Renounceable Rights Issue”. Highlight of this issue include: Funds to complete the manufacture of nanoparticle material and initiate a
Trading Halt
March 23, 2020
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX
Change of Registered Address
March 4, 2020
Imagion Biosystems Limited wishes to advise that its Australian registered office address has changed with immediate effect to: c/o K&L Gates, Level 25, 525 Collins Street,
Investor Presentation — Imagion Biosystems MagSense® Technology
March 3, 2020
President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA
Appendix 4E and 2019 Full Year Results
March 2, 2020
Appendix 4E and 2019 Full Year Results Key Developments Achieved for MagSense® Imaging Technology Imagion Biosystems has released its Appendix 4E and Preliminary Results for
Business Update: Manufacturing Commences
February 26, 2020
Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Notice of ceasing to be a substantial holder
February 14, 2020
Form 605, “Notice of ceasing to be a substantial holder”, has been released to the ASX. Read Form 605.
Imagion Biosystems Appendix 4C – Quarterly
January 30, 2020
Imagion Biosystems has today released its Appendix 4C Quarterly Cash Flow Report and update on Company activities for the quarter ending 31 December 2019. Read